Pacific Edge Directors Give Notice of Retirement

14 March 2024


PACIFIC EDGE DIRECTORS GIVE NOTICE OF RETIREMENT
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
announces the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green.
Mr Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his
governance commitments, and has indicated his intention to retire from the Board following the
appointment of a successor and a structured handover at the end of this year.
Meanwhile, with his family having made new commitments offshore, Mr Green has notified the
Board he does not intend to seek re-election at the company’s next Annual Shareholders
Meeting in September. Mr Green joined the Pacific Edge Board in May 2021.
The Directors have resolved to deliver advance notice of their decision to provide stability and
confidence to Pacific Edge and its stakeholders during the continued uncertainty over the
Medicare coverage status for the company’s Cxbladder tests
1
.
The Board’s Nomination Committee has commenced a process to appoint a new Chair and
consider the recruitment of new Independent Directors.
Mr Gallaher said: “It has always been my declared intention to reduce my governance
commitments when I turned 70, which I will later this year. Pacific Edge is on the threshold of
a new phase of development, with Medicare’s upcoming determination, either way, having
implications for the long-term future and strategy for the company. In the face of such change,
I believe it important that the Board of Pacific Edge now puts in place new governance and
leadership for the long-term.
“I have great confidence in the future of Pacific Edge. We have over the last two years
established a dedicated and skilled management team under Chief Executive Dr Peter
Meintjes to develop our world-leading technology with comprehensive clinical evidence
generation and medical communications. And, we have the capital reserves that position
Pacific Edge for success no matter the Medicare determination. I am looking forward to working
with and supporting the Board and Management over this period of transition.”
Mr Green said: “It is with regret that I provide notice of my intention to step away from the
Pacific Edge Board. With my family moving to New York later this year, I have decided to
rebalance my governance roles. I look forward to supporting Pacific Edge over the coming
months and as it considers new Directors.”
Released for an on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.

1
Novitas the Medicare Administrative Contractor with jurisdiction for Pacific Edge’s US laboratory must either
withdraw or finalize the draft unfavorable Local Coverage Determination (LCD) ‘Genetic testing for Oncology’
(DL39365) by 26 July 2024 (US time). Pacific Edge, which with industry and similarly affected companies has made
numerous representations of the flaws of the LCD and suggested alternatives, has received no indication on when
Novitas will make its position clear.

For more information:
Investors: Media:
Chris Gallaher Richard Inder
Chairman The Project
Pacific Edge P: +64 21 645 643
P: +61 417 556 691

Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than 20 peer reviewed publications for primary detection, surveillance, adjudication of
atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous
ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.